TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded with the mission to develop and commercialize innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company focuses primarily on therapies targeting hematological malignancies, such as relapsed and refractory non-Hodgkin's lymphoma. Recently, TG Therapeutics has expanded its market focus to include treatments for multiple sclerosis, with its product Briumvi® receiving approval from the U.S. FDA for relapsing forms of MS.

Key figures affiliated with TG Therapeutics include Michael S. Weiss, who serves as the Chairman and Chief Executive Officer. The company has garnered attention from notable investors and has achieved significant milestones, including FDA approval for Briumvi®. TG Therapeutics' impact is marked by its fearless pursuit of innovative treatments, contributing to advancements in both oncology and neurology, thereby addressing critical gaps in therapeutic options for patients with serious diseases.